JavaScript NENÍ povolen !

* Zobrazit nápovědu

8 záznamů v PubMed Filtry

Článek

Use of formoterol in the treatment of stuttering. A pilot study

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2009 Sep ; 153 (3) : 199-203.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
ISSN 1804-7521 | 1213-8118
Zdroj

AIMS: Stuttering is a serious health and social problem that can distinctively affect not only the mental development of an individual but also his life possibilities, including social fulfilment and his general life prospects. The etiology of stuttering is however unknown and that is why it is not possible to treat it causally. This pilot study takes into account the hypothesis of bronchial constriction as a negative factor in stuttering and investigates the effect of the long-acting bronchodilator formoterol fumarate on stuttering in 42 patients. METHODS: Patients were divided in 2 groups - A (school children and juveniles) and B (adults 18-25 resistant to other treatment). The medicine was administered once a day in the morning in a dose of 12 microg for the total period of 6 months. The prime outcome parameter - severity of stuttering - was evaluated using the ordinary scale (McGill Pain Questionnaire). The evaluation was done by an examining physician during visits to the centres and by the patients themselves (in cases of the youngest with the assistance of a parent) in a daily diary. RESULTS: A non-parametric pair test (Wilcoxon signed rank test) was used to compare the average marks in the whole set of patients. During the six moth period of administration of Foradil the speech fluency improved. The average number of dysfluent words decreased from 10.5 +/- 1.3 to 6.6 +/-0.97. CONCLUSION: The average mark of speech fluency evaluated by the physicians between the period of non use of Foradil and the six month period after the use of Foradil improved from 2.95 +/- 0.76 to 1.95 +/- 0.56 (as proved by the chi-square test, p<0.0001). The evaluation of speech fluency of balbuties uses the logopedic practices. Other clinical evaluations of speech fluency are not known.

MeSH
bronchodilatancia aplikace a dávkování MeSH
dítě MeSH
dospělí MeSH
ethanolaminy aplikace a dávkování MeSH
formoterol fumarát MeSH
koktavost farmakoterapie patofyziologie MeSH
lidé MeSH
mladiství MeSH
mladý dospělý MeSH
pilotní projekty MeSH
řeč účinky léků MeSH
rozvrh dávkování léků MeSH
stupeň závažnosti nemoci MeSH
Check Tag
dítě MeSH
dospělí MeSH
lidé MeSH
mladiství MeSH
mladý dospělý MeSH
mužské pohlaví MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH
Názvy látek
bronchodilatancia MeSH
ethanolaminy MeSH
formoterol fumarát MeSH

Článek

Budesonide and formoterol in a single inhaler controls asthma in adolescents

International journal of adolescent medicine and health. 2004 Apr-Jun ; 16 (2) : 91-105.

Int J Adolesc Med Health
ISSN 0334-0139
Zdroj

Despite the availability of effective treatments and national guidelines, morbidity from asthma remains high among adolescents. Adolescents need to be considered as a distinct group of individuals with different requirements to those of children and adults. In particular, their non-adherence to prescribed treatment regimens is of concern and is a significant factor contributing to the high rate of morbidity in adolescents. Studies in children aged 4 to 17 years suggest that the combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist effectively controls asthma symptoms in patients who remain symptomatic on ICS alone. In order to improve adherence to therapy, the use of combined therapy with an ICS and a long-acting beta2-agonist in a single inhaler should be considered and the dosing frequency should be adjusted according to the severity of asthma symptoms. This should empower patients with a greater degree of self-management and may be important in helping adolescents feel responsible for the management of their asthma. Results from a recent subanalysis demonstrate that the combination of budesonide and formoterol administered twice daily via a single inhaler (Symbicort Turbuhaler) rapidly gains and maintains control of asthma in adolescents whose asthma is not controlled on ICS alone. It is anticipated that this will lead to improved adherence to therapy in this difficult-to-treat population.

MeSH
adherence pacienta MeSH
aplikace inhalační MeSH
bronchiální astma farmakoterapie MeSH
budesonid aplikace a dávkování terapeutické užití MeSH
ethanolaminy aplikace a dávkování terapeutické užití MeSH
fixní kombinace léků MeSH
hormony kůry nadledvin aplikace a dávkování terapeutické užití MeSH
kombinace léků budesonid a formoterol MeSH
lidé MeSH
mladiství MeSH
nebulizátory a vaporizátory MeSH
randomizované kontrolované studie jako téma MeSH
Check Tag
lidé MeSH
mladiství MeSH
Publikační typ
časopisecké články MeSH
přehledy MeSH
Názvy látek
budesonid MeSH
ethanolaminy MeSH
fixní kombinace léků MeSH
hormony kůry nadledvin MeSH
kombinace léků budesonid a formoterol MeSH

Článek

Pediatric allergy and immunology. 2004 Feb ; 15 (1) : 32-9.

Pediatr Allergy Immunol
ISSN 0905-6157
Zdroj

To compare the dose-related bronchodilator efficacy and tolerability of formoterol (Oxis) Turbuhaler with salmeterol Diskhaler and placebo in children with asthma. A single-dose, randomized, double-blind, incomplete crossover study of 68 children (7-17 years), with moderate-to-severe asthma, 82% receiving inhaled corticosteroids. Patients received four of six treatments [4.5, 9, 18, or 36 microg formoterol (6, 12, 24 or 48 microg metered doses), 50 microg salmeterol (metered dose) or placebo] at 12-h visits, separated by > or =3 days. Forced expiratory volume in 1 s (FEV1), pulse, blood pressure, electrocardiogram, adverse events and urine formoterol were assessed. The therapeutic ratio of formoterol vs. salmeterol was estimated from the efficacy and systemic effects results. All active treatments significantly improved FEV1 compared with placebo. Formoterol 9-36 microg provided dose-related increases over salmeterol in lung function: average 12-h FEV1 (increases of 4.9-8.7%, p < 0.001) and FEV1 at 12 h post-dose (7.0-12.2%, p < 0.001). The onset of effect of formoterol was also significantly faster than salmeterol for doses > or =9 microg. Salmeterol 50 microg was estimated to be equieffective to 3.3 microg formoterol for 12-h average FEV1 and the estimated equieffective dose for a variety of systemic effects was 7.8-13.5 microg formoterol. All treatments were well tolerated. Formoterol (Oxis) Turbuhaler 4.5-36 microg provided dose-related improvements in bronchodilator efficacy in children with asthma. Formoterol > or =9 microg provided superior bronchodilator efficacy over 12 h compared with salmeterol Diskhaler 50 microg with no increase in systemic effects.

MeSH
albuterol aplikace a dávkování analogy a deriváty MeSH
aplikace inhalační MeSH
bronchiální astma diagnóza farmakoterapie MeSH
bronchodilatancia aplikace a dávkování MeSH
dítě MeSH
dvojitá slepá metoda MeSH
ethanolaminy aplikace a dávkování MeSH
formoterol fumarát MeSH
klinické křížové studie MeSH
lidé MeSH
mladiství MeSH
plicní ventilace MeSH
salmeterol xinafoát MeSH
výsledek terapie MeSH
vztah mezi dávkou a účinkem léčiva MeSH
Check Tag
dítě MeSH
lidé MeSH
mladiství MeSH
mužské pohlaví MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
klinické zkoušky MeSH
práce podpořená grantem MeSH
randomizované kontrolované studie MeSH
srovnávací studie MeSH
Názvy látek
albuterol MeSH
bronchodilatancia MeSH
ethanolaminy MeSH
formoterol fumarát MeSH
salmeterol xinafoát MeSH

Článek

Plazmatické hladiny troponinu T u králíků po podání nových antineoplastických látek (Oracinu a Dimefluronu) s daunorubicinem
[Plasma levels of troponin T in rabbits after administration of new antineoplastic agents (Oracin and Dimefluron) and daunorubicin]

Acta medica (Hradec Kralove). Supplementum. 2001 ; 44 (1) : 3-8.

Acta Medica (Hradec Kralove) Suppl
ISSN 1211-247X
Zdroj

Recently, cardiac troponin T (cTnT) has been shown to be a sensitive marker of anthracycline-induced cardiomyopathy. In our study, the cardiotoxicity of repeated i.v. administration (once a week, 10 administrations) of daunorubicin combined with new antineoplastic drugs (with mild side-effects) were followed in two groups of rabbits: 1) Dimefluron (3,9-dimethoxybenfluron hydrochloride-12 mg/kg) + daunorubicin (3 mg/kg), 2) Oracin (6-[2-(2-hydroxyethyl)aminoethyl]-5,11-dioxo-5,6-dihydro-11H- indeno[1,2c]isoquinoline hydrochloride--10 mg/kg) + daunorubicin (3 mg/kg) and compared with the control group (saline--1 ml/kg) and the group with experimentally induced cardiomyopathy (daunorubicin--3 mg/kg). The concentration of cTnT in heparinized plasma samples was measured using commercial kit (Roche). In the control group, plasma levels of cTnT were always within the physiological range (i.e. lower than 0.1 microgram/l) during the experiment. During the development of daunorubicin-induced cardiomyopathy, after the eighth administration of drug, cTnT was significantly higher (0.31 +/- 0.11 microgram/l) in animals with premature deaths compared with the rest of the group (0.04 +/- 0.03 microgram/l). The animals with pathological values of cTnT were at higher risk of premature deaths (P = 0.0006). The combination of daunorubicin either with Oracin or with Dimefluron caused neither significant changes of cTnT levels nor significant deterioration of other followed-up parameters (especially, functional and toxicological parameters). Similarly to the daunorubicin group, the animals with pathological levels of cTnT after the eighth administration of antineoplastic drugs were at higher risk of premature death (P = 0.025). Our results show that the plasma concentration of cardiac troponin T could be a suitable predictive marker of cardiotoxicity of antineoplastic drugs.